Patzke Ciera L, Duffy Alison P, Duong Vu H, El Chaer Firas, Trovato James A, Baer Maria R, Bentzen Søren M, Emadi Ashkan
Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA.
School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
J Clin Med. 2020 Feb 16;9(2):536. doi: 10.3390/jcm9020536.
Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA ( = 0.027). Event-free survival was significantly different in favor of HAM-pegA ( = 0.045), though overall survival was similar between groups. There were no significant differences in toxicities experienced by patients treated with the two regimens, including adverse events of special interest related to pegaspargase (venous thromboembolism, hemorrhage, hepatotoxicity, pancreatitis, and hypersensitivity reactions). HAM-pegA is a novel regimen for relapsed or refractory AML that resulted in improved response rates and similar toxicities compared to CLAG-M.
目前，对于复发或难治性急性髓系白血病（AML）尚无标准治疗方案。我们介绍了我们机构使用CLAG-M或HAM-pegA（一种包含聚乙二醇化天冬酰胺酶的新型方案）的经验。这是一项回顾性比较，34例患者接受CLAG-M作为复发或难治情况下的首次挽救性细胞毒性化疗，10例患者接受HAM-pegA。CLAG-M的综合完全缓解率为47.1%，HAM-pegA为90%（P = 0.027）。无事件生存期HAM-pegA明显更优（P = 0.045），尽管两组的总生存期相似。接受两种方案治疗的患者所经历的毒性，包括与聚乙二醇化天冬酰胺酶相关的特殊关注不良事件（静脉血栓栓塞、出血、肝毒性、胰腺炎和过敏反应），没有显著差异。HAM-pegA是一种用于复发或难治性AML的新型方案，与CLAG-M相比，其缓解率有所提高，毒性相似。
